Default Category
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00
-
Brazos Partners and Cheddar's Inc., Teaching Note
Hardymon, G. Felda; Lerner, Josh; Leamon, AnnTeaching Note HBS-808055-EFinanceTeaching Note for [806069].Starting at €0.00
-
Kleiner-Perkins and Genentech: When Venture Capital Met Science
Hardymon, G. Felda; Nicholas, TomCase HBS-813102-EEntrepreneurshipGenentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into viable therapeutic products with mass market appeal, something that most scientists agreed was at least a decade away. The founders, Herbert Boyer and Robert Swanson had limited fina...Starting at €8.20
-
Apax Partners and Xerium S.A. (Spanish version)
Hardymon, G. Felda; Lerner, Josh; Leamon, AnnCase HBS-806S01EntrepreneurshipIn 2002, Apax Partners had to decide whether to accept a less-than-perfect offer for one of its portfolio companies or to refinance it. This company, a maker of paper industry consumables with a global presence, had been purchased in 1999 and performed extremely well since then. Despite being a solid, cash-generative operation, it didn't excite a lot of interest in the market. An early exit at a good multiple would be helpful for Apax's current f...Starting at €8.20
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20
-
Merck: La administración de Vioxx (B)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S03Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S04Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74